|
[posting]53313210[/posting]Hier ist das Dritte und eigne Produkt(AQS1301) von AQS welches das Potential hat ein Blockbuster zu werden .Wenn alles gut läuft könnte schon im 3Q 2017 der Zulassungsantrag bei der FDA eingereicht werden .AQS hat natürlich die Globalen Rechte will außer Kanada alles auslizenzieren das dürfte saftige Upfront und Milestones zahlungen einbringen . Die Aktie ist wie schon erwähnt übelst unterbewertet mit den lächerlichen $13.5 Millionen . Development and licensing timeline for AQS1301 Phase I: Bioequivalence First dosing expected 4Q2016 Results by 1Q2017 NDA Filing:Expected 3Q2017 Expected Commercial License If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301 Aequus and Corium Enter Into Product Development Collaboration Focused on CNS https://globenewswire.com/news-release/2015/04/28/729508/101… This collaboration builds upon the progress made under the feasibility and preclinical development agreement entered into in May 2014 focusing on Aequus' lead program, AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse. Under the earlier agreement, Corium's advanced proprietary transdermal technology was incorporated into Aequus' lead program, AQS-1301, which enhanced the product's intellectual property position, as well as provided Corium with an economic interest in the program and the option to further increase its interest by co-funding clinical development. Aequus has exclusive worldwide rights to AQS-1301 and intends to seek third-party partners to commercialize this program in the U.S., Europe and Asia, while retaining the commercial rights for Canada. |
|
| aus der Diskussion: | AQS.V (Mkap c$13.5 M) 2 Produkte am Markt + 3 weitere kurz vor Zulassungsantrag |
| Autor (Datum des Eintrages): | Biohero (20.09.16 19:16:48) |
| Beitrag: | 2 von 4,347 (ID:53313819) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |